- QMRO Home
- Blizard Institute
- Centre for Immunobiology
- Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic.
Browse
Administrators only